{"name":"Fondazione Italiana Linfomi - ETS","slug":"fondazione-italiana-linfomi-ets","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":13,"colorKey":"immunology","drugs":[{"name":"R-FM","genericName":"R-FM","slug":"r-fm","indication":"Indolent B-cell lymphomas","status":"phase_3"},{"name":"R2-MANT","genericName":"R2-MANT","slug":"r2-mant","indication":"Mantle cell lymphoma","status":"phase_3"},{"name":"RCHOP o R-miniCHOP at standard doses","genericName":"RCHOP o R-miniCHOP at standard doses","slug":"rchop-o-r-minichop-at-standard-doses","indication":"Follicular lymphoma","status":"phase_3"},{"name":"Treatment plan","genericName":"Treatment plan","slug":"treatment-plan","indication":"Non-Hodgkin's lymphoma","status":"marketed"},{"name":"ABVD and Radiotherapy","genericName":"ABVD and Radiotherapy","slug":"abvd-and-radiotherapy","indication":"Hodgkin lymphoma","status":"phase_2"},{"name":"Bendamustine, Lenalidomide, Rituximab","genericName":"Bendamustine, Lenalidomide, Rituximab","slug":"bendamustine-lenalidomide-rituximab","indication":"Chronic lymphocytic leukemia","status":"phase_2"},{"name":"Bortezomib-Rituximab-Bendamustine","genericName":"Bortezomib-Rituximab-Bendamustine","slug":"bortezomib-rituximab-bendamustine","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_2"},{"name":"Ibritumomab Tiuxetan + Maintenance","genericName":"Ibritumomab Tiuxetan + Maintenance","slug":"ibritumomab-tiuxetan-maintenance","indication":"Relapsed or refractory B-cell non-Hodgkin lymphoma","status":"phase_3"},{"name":"Maintenance weekly x4","genericName":"Maintenance weekly x4","slug":"maintenance-weekly-x4","indication":"Relapsed or refractory diffuse large B-cell lymphoma","status":"phase_3"},{"name":"R-CHOP or R-bendamustine","genericName":"R-CHOP or R-bendamustine","slug":"r-chop-or-r-bendamustine","indication":"B-cell non-Hodgkin lymphoma (various subtypes)","status":"phase_3"},{"name":"R-CHOP with doxorubicin","genericName":"R-CHOP with doxorubicin","slug":"r-chop-with-doxorubicin","indication":"Non-Hodgkin lymphoma","status":"phase_2"},{"name":"R-MANT","genericName":"R-MANT","slug":"r-mant","indication":"Lymphoma (specific subtype under investigation in phase 3 trial by Fondazione Italiana Linfomi)","status":"phase_3"},{"name":"Standard Maintenance","genericName":"Standard Maintenance","slug":"standard-maintenance","indication":"Lymphoma (maintenance phase, specific subtype not specified)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"R-CVP","genericName":"R-CVP","slug":"r-cvp","indication":"Other","status":"marketed"},{"name":"Vincristina","genericName":"Vincristina","slug":"vincristina","indication":"Other","status":"phase_3"},{"name":"BR-DHAP","genericName":"BR-DHAP","slug":"br-dhap","indication":"Other","status":"phase_2"},{"name":"Ciclofosfamide","genericName":"Ciclofosfamide","slug":"ciclofosfamide","indication":"Other","status":"phase_3"},{"name":"Doxorubicina","genericName":"Doxorubicina","slug":"doxorubicina","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"R-CVP","genericName":"R-CVP","slug":"r-cvp","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"R-FM","genericName":"R-FM","slug":"r-fm","phase":"phase_3","mechanism":"R-FM is a rituximab-based chemoimmunotherapy regimen combining rituximab with fludarabine and mitoxantrone for B-cell lymphomas.","indications":["Indolent B-cell lymphomas","Mantle cell lymphoma"],"catalyst":""},{"name":"R2-MANT","genericName":"R2-MANT","slug":"r2-mant","phase":"phase_3","mechanism":"R2-MANT is a mantle cell lymphoma-directed immunotherapy combining rituximab with a novel antitumor mechanism in phase 3 development.","indications":["Mantle cell lymphoma"],"catalyst":""},{"name":"RCHOP o R-miniCHOP at standard doses","genericName":"RCHOP o R-miniCHOP at standard doses","slug":"rchop-o-r-minichop-at-standard-doses","phase":"phase_3","mechanism":"R-CHOP and R-miniCHOP combine chemotherapy and a monoclonal antibody targeting CD20 on B cells.","indications":["Follicular lymphoma","Diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Treatment plan","genericName":"Treatment plan","slug":"treatment-plan","phase":"marketed","mechanism":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.","indications":["Non-Hodgkin's lymphoma","Chronic lymphocytic leukemia","Rheumatoid arthritis"],"catalyst":""},{"name":"Vincristina","genericName":"Vincristina","slug":"vincristina","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABVD and Radiotherapy","genericName":"ABVD and Radiotherapy","slug":"abvd-and-radiotherapy","phase":"phase_2","mechanism":"Brentuximab vedotin targets CD30","indications":["Hodgkin lymphoma","Systemic anaplastic large cell lymphoma"],"catalyst":""},{"name":"BR-DHAP","genericName":"BR-DHAP","slug":"br-dhap","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bendamustine, Lenalidomide, Rituximab","genericName":"Bendamustine, Lenalidomide, Rituximab","slug":"bendamustine-lenalidomide-rituximab","phase":"phase_2","mechanism":"Bendamustine is a chemotherapy medication that works by interfering with DNA replication, Lenalidomide is an immunomodulatory drug that affects the immune system, Rituximab is a monoclonal antibody that targets CD20 on B cells.","indications":["Chronic lymphocytic leukemia","Non-Hodgkin's lymphoma"],"catalyst":""},{"name":"Bortezomib-Rituximab-Bendamustine","genericName":"Bortezomib-Rituximab-Bendamustine","slug":"bortezomib-rituximab-bendamustine","phase":"phase_2","mechanism":"Bortezomib-Rituximab-Bendamustine is a combination of a proteasome inhibitor, a monoclonal antibody, and a chemotherapy agent.","indications":["Relapsed or refractory mantle cell lymphoma"],"catalyst":""},{"name":"Ciclofosfamide","genericName":"Ciclofosfamide","slug":"ciclofosfamide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Doxorubicina","genericName":"Doxorubicina","slug":"doxorubicina","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ibritumomab Tiuxetan + Maintenance","genericName":"Ibritumomab Tiuxetan + Maintenance","slug":"ibritumomab-tiuxetan-maintenance","phase":"phase_3","mechanism":"Ibritumomab tiuxetan is a radiolabeled monoclonal antibody that targets CD20 on B cells and delivers cytotoxic radiation directly to lymphoma cells.","indications":["Relapsed or refractory B-cell non-Hodgkin lymphoma","Follicular lymphoma (maintenance therapy)"],"catalyst":""},{"name":"Maintenance weekly x4","genericName":"Maintenance weekly x4","slug":"maintenance-weekly-x4","phase":"phase_3","mechanism":"This drug targets the CD19 protein on B cells to induce apoptosis.","indications":["Relapsed or refractory diffuse large B-cell lymphoma","Relapsed or refractory follicular lymphoma","Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma","Relapsed or refractory small lymphocytic lymphoma"],"catalyst":""},{"name":"R-CHOP or R-bendamustine","genericName":"R-CHOP or R-bendamustine","slug":"r-chop-or-r-bendamustine","phase":"phase_3","mechanism":"R-CHOP and R-bendamustine are combination chemotherapy regimens that use rituximab (an anti-CD20 monoclonal antibody) combined with cytotoxic chemotherapy agents to kill B-cell lymphomas.","indications":["B-cell non-Hodgkin lymphoma (various subtypes)","Chronic lymphocytic leukemia"],"catalyst":""},{"name":"R-CHOP with doxorubicin","genericName":"R-CHOP with doxorubicin","slug":"r-chop-with-doxorubicin","phase":"phase_2","mechanism":"Rituximab targets CD20 on B cells, doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II.","indications":["Non-Hodgkin lymphoma"],"catalyst":""},{"name":"R-MANT","genericName":"R-MANT","slug":"r-mant","phase":"phase_3","mechanism":"R-MANT is a rituximab-based immunochemotherapy regimen combining rituximab with chemotherapy agents for treatment of lymphoid malignancies.","indications":["Lymphoma (specific subtype under investigation in phase 3 trial by Fondazione Italiana Linfomi)"],"catalyst":""},{"name":"Standard Maintenance","genericName":"Standard Maintenance","slug":"standard-maintenance","phase":"phase_3","mechanism":"Standard Maintenance refers to a continuation therapy regimen rather than a specific drug with a defined molecular mechanism.","indications":["Lymphoma (maintenance phase, specific subtype not specified)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":18,"phaseCounts":{"marketed":2,"phase_3":11,"phase_2":5},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}